SCHEMBL1368433

SCHEMBL1368433

CC(C)(C)OC(=O)Nc1ccc(CC#N)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 2/20 0.56
KMT2A Q03164 2/20 0.54
NPC1 O15118 2/20 0.50
THRB P10828 1/20 0.50
RAB9A P51151 1/20 0.50
LMNA P02545 1/20 0.47
MAPT P10636 1/20 0.47
HTT P42858 1/20 0.47
DRD2 P14416 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
MAPK14 Q16539 1/20 0.46
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PTPN11 Q06124 1/20 0.45
NR1H2 P55055 1/20 0.44
CTSS P25774 4/20 0.44
CTSK P43235 4/20 0.44
NAMPT P43490 2/20 0.44
PSMB8 P28062 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8007420 0.86 CYP17A1 (0.60) CYP17A1DRD2PTGDR2MAPK14PTPN11
SCHEMBL4132208 0.85 CYP17A1 (0.56) CYP17A1DRD2PTGDR2MAPK14PTPN11
SCHEMBL16946760 0.83 CYP17A1 (0.50) CYP17A1DRD2PTGDR2MAPK14PTPN11
SCHEMBL1368399 0.83 AURKA (0.47) CYP17A1NPC1LMNAMAPTHTT
SCHEMBL4171524 0.83 CYP17A1 (0.51) CYP17A1NPC1RAB9ADRD2PTGDR2
SCHEMBL132701 0.82 CYP17A1 (0.76) CYP17A1DRD2PTGDR2MAPK14PTPN11
SCHEMBL13055402 0.82 CYP17A1 (0.59) CYP17A1DRD2PTGDR2MAPK14ALDH1A1
SCHEMBL23336325 0.81 CYP17A1 (0.62) CYP17A1MAPTDRD2PTGDR2MAPK14
SCHEMBL17378103 0.81 KCNQ4 (0.50) CYP17A1NPC1THRBRAB9ANR1H2
SCHEMBL10361607 0.81 CYP17A1 (0.61) CYP17A1RAB9ALMNADRD2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015162536-A1 NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) 2015-10-29 WO claimed
US-20210387954-A1 OXADIAZOLES AS FUNGICIDES PI INDUSTRIES LIMITED (IN) 2021-12-16 US disclosed
WO-2020070611-A1 OXADIAZOLES AS FUNGICIDES PI INDUSTRIES LTD (IN) 2020-04-09 WO disclosed
WO-2015162536-A1 NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) 2015-10-29 WO disclosed
WO-2015162536-A1 NOVEL PROCESS FOR PREPARATION OF MIRABEGRON AND IT'S INTERMEDIATE CALYX CHEMICALS AND PHARMACEUTICALS LTD. (IN) 2015-10-29 WO disclosed
US-8461329-B2 Isoquinoline derivative TAISHO PHARMACEUTICAL CO., LTD. (JP) 2013-06-11 US disclosed
US-20110288293-A1 ISOQUINOLINE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-11-24 US disclosed
EP-2377851-A1 ISOQUINOLINE DERIVATIVE Taisho Pharmaceutical Co., Ltd. (JP) 2011-10-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110288293-A1 ISOQUINOLINE DERIVATIVE HRH1, HRH2, HRH4 CYP17A1 315/4885KMT2A 1467/4885NPC1 161/4885
US-20210387954-A1 OXADIAZOLES AS FUNGICIDES CYP1B1, CYP1A1, OXA1L CYP17A1 64/4885KMT2A 1956/4885NPC1 2945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.